Connect with us


Hot Stocks Alert: Himax Technologies, Inc. (ADR) (NASDAQ:HIMX), SINA Corp. (NASDAQ:SINA), Cirrus Logic, Inc. (NASDAQ:CRUS)



Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) shares increased 1.26% to $8.86. The company on Nov. 7 announced financial results for the third quarter ended September 30, 2013. The third quarter revenues of $192.8 million represented a 1.3% increase from $190.4 million in the third quarter of 2012 and a 6.8% decrease from $207.0 million in the previous quarter of this year. Reported GAAP net income was $12.3 million, or 7.2 cents per diluted ADS, for the third quarter of 2013 up from $10.4 million, or 6.1 cents per diluted ADS, in the corresponding quarter a year ago, and down from $19.4 million, or 11.2 cents per diluted ADS, in the previous quarter. GAAP net income grew 17.9% year over year and declined 36.6% from the previous quarter.

SINA Corp. (NASDAQ:SINA) shares jumped 0.67% to $76.55. The company will announce its unaudited financial results for the third quarter 2013 after the close of market on Tuesday, November 12, 2013. Following the announcement, SINA’s management team will host a conference call from 8p.m. – 9p.m. Eastern Time on November 12, 2013 (or 9a.m. – 10a.m. Beijing Time on November 13, 2013) to present an overview of the Company’s financial performance and business operations.

Cirrus Logic, Inc. (NASDAQ:CRUS) shares declined 11.33% to $19.73. The company announced that the company will present at the following investor conferences: New York City, Nov. 14 – Cirrus Logic Chief Financial Officer Thurman Case to present at the Goldman Sachs US Emerging Growth Conference at 2 p.m. EST at the Marriott Marquis; London, Dec. 4 – Cirrus Logic Chief Executive Officer Jason Rhode to present at the NASDAQ OMX 30th Investor Program at 9:30 a.m. GMT at the Waldorf Hilton.


Top 3 Gainers: Zynga (NASDAQ:ZNGA), Eros International (NYSE:EROS), Borqs Technologies’ (BRQS)




Zynga (NASDAQ:ZNGA) is up 2.5% after Benchmark reiterated its Buy rating in a look-ahead at Q2 earnings. The firm’s expecting a beat and solid guidance for Q3, and it’s raising its guidance for the fiscal year.

Tailwinds from the pandemic won’t dissipate easily, Benchmark suggests, and the videogame maker’s acquisition of Peak (and with it new “forever franchises” in Toon Blast and Toy Blast) will drive audience, bookings, margins and free cash flow, it says. The firm has an $11 price target, now implying 14% upside.

Eros International (NYSE:EROS) is up 5.8% today, making up the last week’s lost ground, after news that its streaming service Eros Now is partnering with Sony India (SNE +2.3%).

That will mean Eros Now’s app is pre-installed on selected Sony smart televisions in India, along with availability on a large base of existing models (Bravia E series and newer).

The country over the past year has seen a 25% growth in demand for smart TVs, fueled by overall industry growth of 15%, to a record 15M units/year.

Borqs Technologies’ (BRQS) personal safety tracker sees strong market with increased orders from the electronics retail chain in the US.

The boost in product demand comes ahead coronavirus pandemic that provides company to expect delivery of 250K units this year. It reflects over 3x the volume delivered in 2019, the year of its launch.

Borqs’ mobile personal safety devices designed particularly for senior citizens come with panic button, location tracking, and fall detection.

Continue Reading


Biotech movers: Pfizer Inc. (PFE), Celgene Corporation (CELG)



Pfizer Inc. (PFE) said on Thursday it received a request for documents as part of a U.S. investigation related to quality issues involving the manufacture of auto-injectors at its Meridian Medical Technologies site.

Pfizer, in a regulatory filing, said it would be producing records in response to the civil investigative demand from the U.S. Attorney’s office for the Southern District of New York.

Why ASDN Could Massively Outperform PFE in 2019

Meridian, a unit of Pfizer that manufactures EpiPen injectors used to deliver an emergency allergy antidote, has been hit by a series of manufacturing problems in recent years. Mylan NV, which markets EpiPens, has recalled tens of thousands of the devices after complaints that some had failed to activate.

Bristol-Myers Squibb has been meeting with shareholders in Boston and New York over the last two weeks to try to salvage its $74 billion purchase of cancer drugmaker Celgene Corporation (CELG), the biggest acquisition announced so far this year.

Why Investors Are Calling ASDN the CELG of the Sky!

The deal, announced in January, was hard sell to Bristol shareholders from the start. The acquisition adds about $32 billion in fresh debt to Bristol’s balance sheet while assuming $20 billion in Celgene’s debt, the companies said at the time. After factoring in debt, the acquisition was the largest health-care deal on record, according to data compiled by Refinitiv.

Now, hedge funds Wellington Management and Starboard Value say the deal doesn’t sit well with them. Bristol has sent executives to New York to meet with institutional investors several times over the last two weeks and met with investors in Boston on Wednesday and Thursday, according to a person who briefed on the meetings.

Bristol-Myers declined to comment.

Continue Reading


Big Losers: Corbus Pharmaceuticals Holdings, Inc. (CRBP), Petróleo Brasileiro S.A. – Petrobras (PBR)



Corbus Pharmaceuticals Holdings, Inc. (CRBP)’s shares slumped as much as 16% to $6.94 on huge volume. The stock has been showing intense sell off suddenly after a bearish article on by Alpha Exposure.

The article stated that Corbus has ties to investors convicted of or alleged to have committed securities fraud. We believe lenabasum has failed its major trials in SSc and CF. Lenabasum was also denied Breakthrough Therapy Designation in SSc. We believe lenabasum will fail in its pivotal SSc and Phase 2b CF trials. We are short Corbus with a price target of $0.50.

Wow the future of Autonomous flight is finally here with the launch of ASDN passenger drone Elroy

Petróleo Brasileiro S.A. – Petrobras (PBR) is expanding its ambitious divestment program and has “bold” plans for sales, the Brazilian state-run oil company’s chief executive said after the firm posted its first annual profit in five years.

On a conference call with analysts to discuss fourth-quarter results, CEO Roberto Castello Branco said selling non-core assets will be key to deleveraging.

Petrobras, as the company is known, can reduce its ratio of net debt to earnings before interest, taxes, depreciation and amortization, or EBITDA, to 1.5 or even to 1, he added.

The University of Chicago-educated CEO, who took the reins in early January, has long been vocal about the need to slim down the sprawling firm and focus on core activities such as exploration and production. Thursday’s comments were some of his most assertive on the matter.

Why Investors Are Calling ASDN the TPC of the Sky!

Continue Reading